Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Non-Current Debt (2019 - 2025)

Outset Medical (OM) has disclosed Non-Current Debt for 7 consecutive years, with $96.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 51.24% to $96.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.2 million, a 51.24% decrease, with the full-year FY2025 number at $96.2 million, down 51.24% from a year prior.
  • Non-Current Debt was $96.2 million for Q4 2025 at Outset Medical, up from $95.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $197.4 million in Q4 2024 to a low of $28.8 million in Q2 2022.
  • A 5-year average of $94.6 million and a median of $95.9 million in 2025 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: surged 235.45% in 2023, then plummeted 52.18% in 2025.
  • Outset Medical's Non-Current Debt stood at $29.8 million in 2021, then soared by 223.69% to $96.3 million in 2022, then surged by 35.06% to $130.1 million in 2023, then skyrocketed by 51.7% to $197.4 million in 2024, then tumbled by 51.24% to $96.2 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Non-Current Debt are $96.2 million (Q4 2025), $95.5 million (Q3 2025), and $94.8 million (Q2 2025).